Pacific Biosciences of California Inc (PACB)
1.645
+0.18
(+12.67%)
USD |
NASDAQ |
Apr 19, 12:37
Pacific Biosciences of California Research and Development Expense (Quarterly): 44.54M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 44.54M |
| September 30, 2023 | 47.51M |
| June 30, 2023 | 46.17M |
| March 31, 2023 | 48.94M |
| December 31, 2022 | 42.62M |
| September 30, 2022 | 47.09M |
| June 30, 2022 | 50.35M |
| March 31, 2022 | 52.94M |
| December 31, 2021 | 42.58M |
| September 30, 2021 | 27.51M |
| June 30, 2021 | 22.27M |
| March 31, 2021 | 20.55M |
| December 31, 2020 | 17.42M |
| September 30, 2020 | 16.47M |
| June 30, 2020 | 15.01M |
| March 31, 2020 | 15.25M |
| December 31, 2019 | 14.27M |
| September 30, 2019 | 14.96M |
| June 30, 2019 | 14.91M |
| March 31, 2019 | 15.48M |
| December 31, 2018 | 16.26M |
| September 30, 2018 | 14.36M |
| June 30, 2018 | 15.66M |
| March 31, 2018 | 16.31M |
| December 31, 2017 | 15.63M |
| Date | Value |
|---|---|
| September 30, 2017 | 15.84M |
| June 30, 2017 | 16.88M |
| March 31, 2017 | 16.97M |
| December 31, 2016 | 16.26M |
| September 30, 2016 | 17.48M |
| June 30, 2016 | 17.52M |
| March 31, 2016 | 16.36M |
| December 31, 2015 | 14.75M |
| September 30, 2015 | 16.16M |
| June 30, 2015 | 15.04M |
| March 31, 2015 | 14.48M |
| December 31, 2014 | 12.33M |
| September 30, 2014 | 11.69M |
| June 30, 2014 | 12.44M |
| March 31, 2014 | 11.77M |
| December 31, 2013 | 11.13M |
| September 30, 2013 | 10.42M |
| June 30, 2013 | 11.68M |
| March 31, 2013 | 11.98M |
| December 31, 2012 | 11.65M |
| September 30, 2012 | 12.63M |
| June 30, 2012 | 11.27M |
| March 31, 2012 | 12.07M |
| December 31, 2011 | 12.42M |
| September 30, 2011 | 20.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
14.27M
Minimum
Dec 2019
52.94M
Maximum
Mar 2022
31.65M
Average
27.51M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Integer Holdings Corp | 13.26M |
| Cerus Corp | 14.29M |
| Axogen Inc | 7.301M |
| AVITA Medical Inc | 6.765M |
| Intellia Therapeutics Inc | 108.98M |